Capsazepine Found to Shrink Oral Tumors
the Cancer Therapy Advisor take:
Each year approximately 40,000 patients in the United States are diagnosed with oral squamous cell carcinoma, which is the eighth most common cancer, and the disease will cause 8,000 deaths annually.
About 60% of patients have large tumors before they seek medical help, which results in a 30% survival rate 5 years after diagnosis. According to a study published in Oral Oncology, capsazepine has been shown to shrink oral cancers without harming healthy surrounding tissue. First author Cara B. Gonzales, DDS, PhD, and researchers at the School of Dentistry and School of Medicine at The University of Texas Health Science Center developed capsazepine as an agent to block TRPV1, which is a calcium channel in neurons. TRPV1 sends pain signals to the brain when stimulated.
Since capsazepine hinders tumor-secreted factors from stimulating TRPV1k , researchers believed the agent could reduce oral cancer pain. After they conducted their study, researchers found that capsazepine demonstrated anti-cancer activity as well, which may be linked to its capacity to increase oxidative tumor damage.
Researchers suspect that enhanced oxidative stress created by capsazepine causes apoptosis, or cell death, in tumor cells. Gonzales said the next step is to test how the new therapy fares against metastatic disease.
Mouse models treated with an agent called capsazepine showed dramatic tumor shrinkage.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma